Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PALI

Palisade Bio Inc

Apr 17 • 04:00PM ET

2.40

+0.07 3.00 %

Healthcare • Biotechnology • USA • NASD

Peers: ONCT NRT ENTA CYPH GERN LVTX IMMP IKT HEPA

| Held by: VXF SURI AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.48	Insider Own	3.75%	Shs Outstand	165.88M	Perf Week	31.87%
Market Cap	398.12M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	0.07%	Shs Float	159.66M	Perf Month	21.83%
Enterprise Value	264.81M	PEG	-	EPS next Q	-0.04	Inst Own	81.84%	Short Float	16.14%	Perf Quarter	37.14%
Income	-16.78M	P/S	-	EPS this Y	22.92%	Inst Trans	131.39%	Short Ratio	6.50	Perf Half Y	38.73%
Sales	0.00M	P/B	2.96	EPS next Y	-24.17%	ROA	-23.11%	Short Interest	25.77M	Perf YTD	2.13%
Book/sh	0.81	P/C	2.98	EPS next 5Y	-11.42%	ROE	-24.52%	52W High	2.64 -9.09%	Perf Year	233.38%
Cash/sh	0.80	P/FCF	-	EPS past 3/5Y	89.33% 88.75%	ROIC	-12.97%	52W Low	0.53 352.83%	Perf 3Y	-91.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.53% 9.58%	Perf 5Y	-99.96%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	88.60%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	28.95	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	68.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	28.95	EPS Q/Q	98.00%	SMA20	20.94%	Beta	1.65	Target Price	11.22
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	28.88%	Rel Volume	0.89	Prev Close	2.33
Employees	14	LT Debt/Eq	0.00	Earnings	Mar 25	SMA200	56.03%	Avg Volume	3.96M	Price	2.40
IPO	Dec 20, 2006	Option/Short	No / Yes	EPS/Sales Surpr.	2.78% -	Trades		Volume	3,532,954	Change	3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Initiated	Wolfe Research	Outperform	$7
Mar-26-26	Initiated	H.C. Wainwright	Buy	$7
Feb-25-26	Initiated	Stifel	Buy	$5
Jan-09-26	Initiated	B. Riley Securities	Buy	$7
Dec-29-25	Initiated	Piper Sandler	Overweight	$25

Apr-16-26 08:50AM	Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 (GlobeNewswire)
Apr-08-26 09:00AM	Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference (GlobeNewswire)
Mar-30-26 04:01PM	Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease (GlobeNewswire) -11.00%
Mar-02-26 09:00AM	Palisade Bio Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 06:30AM	Palisade Bio Details PALI-2108 UC, Crohns Plans and Cash Runway Into 2029 at Oppenheimer Conference (MarketBeat)
08:40AM	Loading…
Feb-23-26 08:40AM	Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 (GlobeNewswire)
Feb-17-26 08:45AM	Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board (GlobeNewswire)
Feb-09-26 09:00AM	Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire)
Feb-05-26 08:45AM	Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.06%
Jan-29-26 08:45AM	Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board (GlobeNewswire)
Jan-16-26 08:30AM	Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences (GlobeNewswire) -5.14%
Jan-07-26 08:15AM	Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 (GlobeNewswire) +5.21%
Dec-30-25 08:35AM	Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.) +15.35%
Dec-25-25 10:37AM	Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results (Insider Monkey)
12:00PM	Loading…
Dec-19-25 12:00PM	Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know (Zacks) +9.58%
Dec-02-25 08:45AM	Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development (GlobeNewswire)
Nov-25-25 08:45AM	Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) -5.70%
Nov-10-25 09:55AM	Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher (Zacks) +5.36%
Nov-06-25 12:00PM	All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy (Zacks)
Oct-28-25 08:45AM	Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations (GlobeNewswire) +11.45%
Oct-20-25 08:45AM	Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire) +6.90%
Oct-13-25 08:45AM	Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 (GlobeNewswire) -7.50%
Oct-09-25 05:00PM	Palisade Bio Announces Cancellation of Special Meeting of Stockholders (GlobeNewswire)
Oct-02-25 04:05PM	Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option (GlobeNewswire) +29.77% -5.88%
Oct-01-25 09:20AM	Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +52.38%
Sep-26-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) +16.20%
Sep-18-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Sep-17-25 09:00AM	Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data (GlobeNewswire)
Sep-05-25 08:45AM	Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire)
09:00AM	Loading…
Aug-25-25 09:00AM	Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 (GlobeNewswire) -8.46%
Aug-11-25 07:04AM	Palisade reports outcomes from Phase Ib ulcerative colitis study (Clinical Trials Arena) -6.34%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -12.16%
09:15AM	Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 (GlobeNewswire)
Jul-31-25 08:45AM	Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China (GlobeNewswire)
Jul-30-25 06:30AM	PALISADES ANNOUNCES CLOSING OF $8,251,800 LOAN WITH STRATEGIC INVESTOR (PR Newswire)
Jul-23-25 08:00PM	Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million (GlobeNewswire) +41.86% -9.02%
Jul-22-25 08:45AM	Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire) -9.20%
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-09-25 08:45AM	Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors (GlobeNewswire) +5.41%
May-27-25 08:30AM	Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis (GlobeNewswire)
May-06-25 08:30AM	Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases (GlobeNewswire) +6.07%
May-01-25 08:30AM	Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit (GlobeNewswire)
Apr-09-25 08:30AM	Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire)
Mar-14-25 08:30AM	Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire) +8.99%
Mar-12-25 08:30AM	Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 (GlobeNewswire) +11.70%
Mar-04-25 08:30AM	Palisade Bio Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Feb-20-25 08:45AM	Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Feb-19-25 09:00AM	Palisade Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-10-25 08:45AM	Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -7.20%
Jan-29-25 08:45AM	Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress (GlobeNewswire)
Jan-22-25 08:00AM	Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -5.30%
Jan-16-25 08:00AM	Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis (GlobeNewswire) -5.68%
Jan-03-25 05:20PM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.79%
Dec-17-24 08:30AM	Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board (GlobeNewswire)
Dec-13-24 04:05PM	Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) -25.00%
Dec-12-24 12:05PM	Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) +68.57%
Dec-03-24 08:15AM	Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects (GlobeNewswire) -5.00%
Nov-21-24 08:15AM	Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) (GlobeNewswire)
Nov-14-24 09:00AM	Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit (GlobeNewswire) +19.09%
Nov-12-24 08:45AM	Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 (GlobeNewswire)
Nov-07-24 08:30AM	Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) (GlobeNewswire)
Oct-31-24 08:30AM	Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -12.26%
Oct-15-24 08:00AM	Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-10-24 08:30AM	Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Oct-08-24 08:00AM	Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -7.10%
Sep-25-24 08:00AM	Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -9.66%
Sep-16-24 08:00AM	Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies (GlobeNewswire)
Sep-05-24 08:00AM	Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification (GlobeNewswire)
Aug-19-24 08:00AM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.38%
Aug-13-24 08:05AM	Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-24 08:00AM	Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis (GlobeNewswire)
Jul-31-24 09:15AM	Palisade Bio Participates in Virtual Investor What this Means Segment (GlobeNewswire) +11.68%
Jul-29-24 08:30AM	Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 (GlobeNewswire) -12.08%
Jul-19-24 08:30AM	Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jul-11-24 08:00AM	Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product (GlobeNewswire)
Jun-24-24 09:00AM	Palisade Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
Jun-21-24 08:15AM	Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 09:55AM	Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now (Zacks)
Jun-11-24 08:30AM	Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jun-10-24 09:15AM	Palisade Bio to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-21-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models (GlobeNewswire) -7.52%
May-14-24 08:05AM	Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 10:53PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024 (InvestorPlace) -7.30%
May-07-24 08:30AM	Palisade Bio Appoints Margery Fischbein to its Board of Directors (GlobeNewswire) -6.62%
07:30AM	Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-02-24 08:30AM	Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-01-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) (GlobeNewswire) +17.41%
Apr-23-24 08:30AM	Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach (GlobeNewswire) +20.08%
Apr-16-24 11:22AM	Why Is Palisade Bio (PALI) Stock Up 57% Today? (InvestorPlace) +42.55%
08:30AM	Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool (GlobeNewswire)
Apr-11-24 09:15AM	Palisade Bio to Participate in the Virtual Investor Lunch Break Event (GlobeNewswire) +7.62%
Apr-10-24 08:15AM	Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis (GlobeNewswire) -24.91%
Apr-03-24 05:30PM	Palisade Bio Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
Mar-27-24 08:00AM	Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +6.04%
Mar-26-24 11:52PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023 (InvestorPlace)
Feb-15-24 08:35AM	Palisade Bio to Present at Digestive Disease Week (DDW) 2024 (GlobeNewswire)
Feb-13-24 08:35AM	Palisade Bio Provides Corporate Update and Reiterates Guidance (GlobeNewswire)

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies for inflammatory bowel diseases. Its programs include PALI-2108 and LB1148. The company was founded on September 6, 2011 and is headquartered in Denver, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Mitchell Lawrence	Chief Medical Officer	Feb 12 '26	Sale	1.75	1,989	3,481	13,263	Feb 13 08:10 PM
Finley John David	CEO, CFO	Feb 12 '26	Sale	1.75	3,896	6,818	27,353	Feb 13 08:07 PM
Williams Donald Allen	Director	Jan 16 '26	Buy	1.67	5,000	8,356	10,728	Jan 21 04:05 PM
Williams Donald Allen	Director	Jan 09 '26	Buy	1.88	5,000	9,400	5,728	Jan 13 09:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PALI

Palisade Bio Inc

Upgrade your Finviz experience